Since then, GLP-1 RAs have become a cornerstone treatment option for T2DM, as it causes a mean 0.8-1.5% reduction in HbA1c with the minimum associated risk of hypoglycemia. This evidence concerns the gene GLP1R and Hypoglycemia.